

Dok Hyun Yoon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6362216/publications.pdf>

Version: 2024-02-01

190
papers

2,919
citations

257450

24
h-index

254184

43
g-index

194
all docs

194
docs citations

194
times ranked

4384
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. <i>Cancer Research and Treatment</i> , 2023, 55, 325-333.	3.0	2
2	BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. <i>Modern Pathology</i> , 2022, 35, 480-488.	5.5	6
3	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	1.6	160
4	Comparison of clinical and laboratory characteristics of nonsecretory multiple myeloma and secretory multiple myeloma in a tertiary care hospital. <i>International Journal of Laboratory Hematology</i> , 2022, , .	1.3	0
5	Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma. <i>Haematologica</i> , 2022, 107, 1999-2003.	3.5	2
6	Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2022, 101, 1217-1226.	1.8	2
7	Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). <i>International Journal of Hematology</i> , 2022, , 1.	1.6	0
8	Abstract CT127: Trial in progress: A phase II, open-label, multicenter study of capivasertib, a potent, oral pan-AKT inhibitor in patients with relapsed or refractory B-cell non-hodgkin lymphoma (CAPITAL). <i>Cancer Research</i> , 2022, 82, CT127-CT127.	0.9	0
9	Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7560-7560.	1.6	0
10	A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7563-7563.	1.6	5
11	CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8070-TPS8070.	1.6	1
12	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 4003-4017.	7.0	15
13	Prognostic factors for relapse and survival among patients with ocular adnexal lymphoma: validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification. <i>British Journal of Ophthalmology</i> , 2021, 105, 279-284.	3.9	13
14	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1205-1208.	2.4	13
15	A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β_2 -microglobulin levels. <i>British Journal of Haematology</i> , 2021, 193, 307-315.	2.5	4
16	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis. <i>European Radiology</i> , 2021, 31, 152-162.	4.5	12
17	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2021, 113, 81-91.	1.6	3
18	Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study. <i>Cancer Research and Treatment</i> , 2021, 53, 270-278.	3.0	1

#	ARTICLE	IF	CITATIONS
19	Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients. <i>Cancer Imaging</i> , 2021, 21, 5.	2.8	5
20	Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 25.	17.0	41
21	Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disordersâ€“diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 2880.	3.3	5
22	Realâ€“world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. <i>Cancer Communications</i> , 2021, 41, 275-278.	9.2	4
23	The limited role of comprehensive staging workâ€“up in ocular adnexal extranodal marginal zone lymphoma of mucosaâ€“associated lymphoid tissue type (MALToma) with excellent prognosis. <i>British Journal of Haematology</i> , 2021, 193, 848-851.	2.5	4
24	Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intentâ€“based analysis. <i>Blood Advances</i> , 2021, 5, 2142-2152.	5.2	23
25	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	1.6	132
26	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100126.	2.9	30
27	Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma. <i>Annals of Laboratory Medicine</i> , 2021, 41, 259-267.	2.5	1
28	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. <i>International Journal of Hematology</i> , 2021, 114, 355-362.	1.6	1
29	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2529-2539.	1.8	12
30	Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. <i>Current Problems in Cancer</i> , 2021, 46, 100788.	2.0	1
31	Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 330-337.	1.1	5
32	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 183-183.	1.4	8
33	A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies. <i>Blood</i> , 2021, 138, 3562-3562.	1.4	1
34	Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1376-1376.	1.4	3
35	TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2021, 138, 3545-3545.	1.4	2
36	Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea. <i>Blood Research</i> , 2021, , .	1.3	3

#	ARTICLE	IF	CITATIONS
37	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2021, .	3.0	4
38	JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma. <i>Annals of Laboratory Medicine</i> , 2020, 40, 1-6.	2.5	0
39	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2020, 99, 255-264.	1.8	3
40	Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia and Lymphoma</i> , 2020, 61, 1119-1125.	1.3	5
41	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164). <i>TJ ETQq1 1 0.784314 ogBT /Over</i>		
42	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , 2020, 99, 309-319.	1.8	5
43	Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia. <i>Annals of Laboratory Medicine</i> , 2020, 40, 193-200.	2.5	5
44	Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 594692.	2.8	8
45	First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. <i>Cancers</i> , 2020, 12, 2192.	3.7	16
46	Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09). <i>Annals of Hematology</i> , 2020, 99, 2831-2836.	1.8	3
47	Clinicopathological and prognostic significance of <i>BCL2</i> , <i>BCL6</i> , <i>MYC</i> , and <i>IRF4</i> copy number gains and translocations in follicular lymphoma: a study by FISH analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 3342-3350.	1.3	2
48	Assessment of NK Cell Activity Based on NK Cell-Specific Receptor Synergy in Peripheral Blood Mononuclear Cells and Whole Blood. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8112.	4.1	2
49	Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. <i>Transplant International</i> , 2020, 33, 1211-1219.	1.6	3
50	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. <i>Journal of Hematology and Oncology</i> , 2020, 13, 21.	17.0	17
51	Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. <i>Blood</i> , 2020, 136, 2548-2556.	1.4	17
52	Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2. <i>Scientific Reports</i> , 2020, 10, 10680.	3.3	5
53	Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. <i>Cancer Imaging</i> , 2020, 20, 14.	2.8	27
54	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (5417906OLYM2003: IVORY study): results of the final analysis. <i>Annals of Hematology</i> , 2020, 99, 1283-1291.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 329.	2.8	8
56	The clinical outcomes of rituximab biosimilar CT-P10 (Truxima [®]) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience. <i>Leukemia and Lymphoma</i> , 2020, 61, 1575-1583.	1.3	17
57	A Phase 1 Study of the Combination of MG4101, <i>Ex Vivo</i> -Expanded Allogeneic NK Cells and Rituximab for Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 14-15.	1.4	8
58	Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. <i>Blood</i> , 2020, 136, 45-46.	1.4	22
59	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 37-38.	1.4	37
60	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30 ⁺ Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labelled Phase II Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 374-387.	3.0	26
61	Breast implant-associated anaplastic large cell lymphoma: the first South Korean case. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 432-434.	1.1	5
62	POEMS Syndrome: Bone Marrow, Laboratory, and Clinical Findings in 24 Korean Patients. <i>Annals of Laboratory Medicine</i> , 2019, 39, 561-565.	2.5	3
63	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. <i>BMC Cancer</i> , 2019, 19, 1080.	2.6	17
64	Phase II study of R ² CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	12
65	Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 2541-2550.	1.8	43
66	A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). <i>Anticancer Research</i> , 2019, 39, 5123-5133.	1.1	23
67	Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis. <i>International Journal of Hematology</i> , 2019, 110, 86-94.	1.6	19
68	Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma. <i>Scientific Reports</i> , 2019, 9, 7193.	3.3	17
69	Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. <i>Annals of Hematology</i> , 2019, 98, 1657-1664.	1.8	10
70	Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis. <i>Transfusion</i> , 2019, 59, 1781-1788.	1.6	0
71	Feasibility of reduced-dose CT of the head and neck with iterative reconstruction: a phantom and prospective clinical study. <i>Acta Radiologica</i> , 2019, 60, 1457-1464.	1.1	0
72	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302.	3.3	12

#	ARTICLE	IF	CITATIONS
73	An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3) Tj ETQq1 1 0.784314 rgBT / Dv 4728-4728.	1.4	3
74	Body Cavityâ€‘Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. Cancer Research and Treatment, 2019, 51, 1302-1312.	3.0	6
75	Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma. Blood, 2019, 134, 1585-1585.	1.4	26
76	The Predictors and Prevention of the Central Nervous System Relapse in Patients with Extranodal NK/T Cell Lymphoma, Nasal Type. Blood, 2019, 134, 2847-2847.	1.4	0
77	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. Annals of Hematology, 2018, 97, 1437-1443.	1.8	16
78	Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea. Acta Haematologica, 2018, 139, 185-192.	1.4	8
79	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. Investigational New Drugs, 2018, 36, 877-885.	2.6	5
80	Epsteinâ€‘Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin’s lymphoma. Hematological Oncology, 2018, 36, 182-188.	1.7	18
81	Effect of an Arm Traction Device on Image Quality and Radiation Exposure during Neck CT: A Prospective Study. American Journal of Neuroradiology, 2018, 39, 151-155.	2.4	7
82	Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. Annals of Hematology, 2018, 97, 1851-1857.	1.8	5
83	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. Annals of Hematology, 2018, 97, 2363-2372.	1.8	13
84	Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. International Journal of Molecular Sciences, 2018, 19, 340.	4.1	157
85	Central Nervous System Relapse in Patients with Peripheral T-Cell Lymphoma. Blood, 2018, 132, 5346-5346.	1.4	1
86	Prognostic Value of Serum Beta-2 Microglobulin during and after Completing Chemotherapy in Marginal Zone Lymphoma. Blood, 2018, 132, 5335-5335.	1.4	0
87	Central Nervous System Relapse in Patients with Extranodal NK/T-Cell Lymphoma, Nasal Type. Blood, 2018, 132, 1634-1634.	1.4	0
88	RGS1 expression is associated with poor prognosis in multiple myeloma. Journal of Clinical Pathology, 2017, 70, 202-207.	2.0	27
89	Sexual problems in male vs. female non-Hodgkin lymphoma survivors: prevalence, correlates, and associations with health-related quality of life. Annals of Hematology, 2017, 96, 739-747.	1.8	18
90	Electrophysiologic features of POEMS syndrome compared with MGUSâ€‘related neuropathy. Muscle and Nerve, 2017, 56, E73-E77.	2.2	7

#	ARTICLE	IF	CITATIONS
91	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. <i>Cancer Medicine</i> , 2017, 6, 100-108.	2.8	5
92	PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma. <i>Annals of Hematology</i> , 2017, 96, 1883-1890.	1.8	37
93	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. <i>American Journal of Hematology</i> , 2017, 92, 1280-1286.	4.1	34
94	Interim 18F-FDG PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. <i>Annals of Hematology</i> , 2017, 96, 1509-1515.	1.8	15
95	Methotrexate elimination and toxicity: <i>MTHFR</i> C677T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate. <i>Hematological Oncology</i> , 2017, 35, 504-509.	1.7	13
96	A Randomized Feasibility Study of ¹⁸ F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 563-568.	5.0	40
97	Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients. <i>Blood Research</i> , 2017, 52, 125.	1.3	7
98	Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma. <i>Blood Research</i> , 2017, 52, 270.	1.3	6
99	Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis. <i>Blood Research</i> , 2017, 52, 221.	1.3	4
100	Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. <i>Blood Research</i> , 2017, 52, 285.	1.3	19
101	Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. <i>Blood Research</i> , 2017, 52, 200.	1.3	9
102	Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). <i>Oncotarget</i> , 2017, 8, 13367-13374.	1.8	6
103	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526.	1.8	16
104	The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. <i>Oncotarget</i> , 2017, 8, 58122-58132.	1.8	13
105	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92171-92182.	1.8	12
106	GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 152-158.	1.1	20
107	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. <i>Blood Research</i> , 2016, 51, 193.	1.3	6
108	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. <i>Oncotarget</i> , 2016, 7, 76934-76943.	1.8	33

#	ARTICLE	IF	CITATIONS
109	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. <i>Annals of Hematology</i> , 2016, 95, 911-919.	1.8	4
110	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. <i>Tumor Biology</i> , 2016, 37, 7507-7514.	1.8	40
111	Bone marrow involvement is not associated with the clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 942-948.	1.5	10
112	Pneumocystis pneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy. <i>Medical Mycology</i> , 2016, 55, myw095.	0.7	4
113	A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy. <i>Annals of Hematology</i> , 2016, 95, 1249-1258.	1.8	13
114	Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 865-873.	2.3	10
115	Recurrence patterns of mucosa-associated lymphoid tissue lymphoma after definitive radiation treatment: A single center experience. <i>Hematology</i> , 2016, 21, 542-548.	1.5	5
116	Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. <i>Hematological Oncology</i> , 2016, 34, 22-27.	1.7	25
117	Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma. <i>Annals of Hematology</i> , 2016, 95, 801-808.	1.8	18
118	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	10.7	285
119	Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. <i>Annals of Hematology</i> , 2016, 95, 603-611.	1.8	7
120	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 1406-1412.	1.3	4
121	Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients. <i>Experimental Hematology</i> , 2016, 44, 3-13.	0.4	7
122	The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1820-1820.	1.4	19
123	Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide Conditioning in Patients with Primary Central Nervous System Lymphoma: A Remarkable Outcome Form Single-Center Experience. <i>Blood</i> , 2016, 128, 3462-3462.	1.4	1
124	Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). <i>Oncotarget</i> , 2016, 7, 85584-85591.	1.8	36
125	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. <i>Oncotarget</i> , 2016, 7, 72033-72043.	1.8	14
126	Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 605-607.	1.7	4

#	ARTICLE	IF	CITATIONS
127	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445.	1.4	0
128	A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial. <i>Blood</i> , 2016, 128, 1823-1823.	1.4	0
129	Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 5683-5683.	1.4	0
130	Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. <i>Cancer</i> , 2015, 121, 2612-2617.	4.1	63
131	Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression. <i>International Journal of Experimental Pathology</i> , 2015, 96, 232-239.	1.3	4
132	Engagement of CD99 Reduces AP-1 Activity by Inducing BATF in the Human Multiple Myeloma Cell Line RPMI8226. <i>Immune Network</i> , 2015, 15, 260.	3.6	8
133	Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. <i>Blood Research</i> , 2015, 50, 242.	1.3	15
134	Primary Histiocytic Sarcoma of the Central Nervous System. <i>Cancer Research and Treatment</i> , 2015, 47, 322-328.	3.0	21
135	The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age. <i>Hematological Oncology</i> , 2015, 33, 133-140.	1.7	16
136	Randomized Phase 2 Trial of S1 and Oxaliplatin-Based Chemoradiotherapy With or Without Induction Chemotherapy for Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 489-496.	0.8	39
137	$\text{TCL}1$ expression predicts overall survival in patients with mantle cell lymphoma. <i>European Journal of Haematology</i> , 2015, 95, 583-594.	2.2	8
138	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1597-1604.	2.0	76
139	Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 2630-2636.	1.3	11
140	Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. <i>International Journal of Hematology</i> , 2015, 102, 420-425.	1.6	3
141	Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient. <i>Cancer Research and Treatment</i> , 2015, 47, 539-543.	3.0	3
142	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. <i>Cancer Research and Treatment</i> , 2015, 47, 173-181.	3.0	10
143	The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 675-683.	1.7	2
144	CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma. <i>PLoS ONE</i> , 2014, 9, e87066.	2.5	46

#	ARTICLE	IF	CITATIONS
145	Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems. <i>Journal of Korean Medical Science</i> , 2014, 29, 53.	2.5	26
146	Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. <i>Blood Research</i> , 2014, 49, 148.	1.3	48
147	Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience. <i>Blood Research</i> , 2014, 49, 253.	1.3	26
148	Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience. <i>Blood Research</i> , 2014, 49, 170.	1.3	14
149	Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience. <i>Blood Research</i> , 2014, 49, 42.	1.3	5
150	Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. <i>Blood Research</i> , 2014, 49, 115.	1.3	3
151	Case series of precursor B-cell lymphoblastic lymphoma. <i>Blood Research</i> , 2014, 49, 270.	1.3	1
152	Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	4
153	A Case of Type II Enteropathy-Associated T-Cell Lymphoma with Epstein-Barr Virus Positivity. <i>Korean Journal of Pathology</i> , 2014, 48, 426-429.	1.3	6
154	LGALS3 as a prognostic factor for classical Hodgkin's lymphoma. <i>Modern Pathology</i> , 2014, 27, 1338-1344.	5.5	16
155	Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases. <i>Korean Journal of Pathology</i> , 2014, 48, 209.	1.3	9
156	The Clinical Impact of Thalidomide Maintenance on Progression Free Survival and Postrelapse Survival after Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple myeloma. <i>Blood</i> , 2014, 124, 3975-3975.	1.4	0
157	Proposal of New Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2014, 124, 1668-1668.	1.4	0
158	The Prognostic Impact of Inflammatory Factors for Survival in Patients with Newly Diagnosed Multiple Myeloma Who Were Treated with Thalidomide Containing Induction Chemotherapy Underwent Autologous Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 5896-5896.	1.4	0
159	¹⁸ F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 249-256.	1.0	10
160	Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma. <i>Korean Journal of Pathology</i> , 2013, 47, 526.	1.3	27
161	Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma. <i>Blood Research</i> , 2013, 48, 266.	1.3	16
162	Prognostic Significance Of Positron Emission Tomography-Computed Tomography In Patients With Marginal Zone Lymphoma. <i>Blood</i> , 2013, 122, 4324-4324.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Prognostic Impact Of Beta-2 Microglobulin In Patients With Non-Gastric Marginal Zone Lymphoma. <i>Blood</i> , 2013, 122, 4297-4297.	1.4	0
164	CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2012, 88, 292-305.	2.2	46
165	Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. <i>Investigational New Drugs</i> , 2012, 30, 819-827.	2.6	24
166	Clinical Significance of Immunoglobulin Isotype Switching in Patients with Multiple Myeloma. <i>Blood</i> , 2012, 120, 4980-4980.	1.4	0
167	Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement.. <i>Blood</i> , 2012, 120, 2683-2683.	1.4	0
168	Peripheral Blood Hematopoietic Progenitor Cell (HPC) Counts At Autologous Stem Cell Collection (ASCC) Are Associated with Prognosis in Multiple Myeloma. <i>Blood</i> , 2012, 120, 4412-4412.	1.4	0
169	Prognostic Value of Positron Emission Tomography- Computed Tomography in Patients with Marginal Zone Lymphoma. <i>Blood</i> , 2012, 120, 5084-5084.	1.4	1
170	The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. <i>Anticancer Research</i> , 2012, 32, 1681-8.	1.1	21
171	A phase I study of S-1 treatment with a 3Âweek schedule in advanced biliary cancer patients with or without hepatic dysfunction. <i>Investigational New Drugs</i> , 2011, 29, 332-339.	2.6	2
172	Expression of JLI in Burkitt lymphoma is associated with improved overall survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 353-359.	2.8	3
173	Usefulness of Interim FDG-PET After Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Sequential Induction Chemotherapy Followed by Concurrent Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 118-125.	0.8	25
174	FDG-PET as a Potential Tool for Selecting Patients with Advanced NonâSmall Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 5093-5100.	7.0	16
175	Yttrium-90-Ibritumomab Tiuxetan and BuCyE High-Dose Chemotherapy Compared with BuCyE Alone As Conditioning Regimen in Patients with B-Cell Non-Hodgkin Lymphoma: IPI Matched Case Control Study At a Single Center,. <i>Blood</i> , 2011, 118, 3703-3703.	1.4	0
176	The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2011, 118, 2661-2661.	1.4	0
177	Associations of Methylene Tetrahydrofolate Reductase Polymorphism and Methotrexate-Related Toxicities in Korean Treated for Malignant Lymphoma. <i>Blood</i> , 2011, 118, 1607-1607.	1.4	0
178	Remobilization with High Dose Methotrexate and Cytarabine in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Previously Failing Mobilization with Chemotherapy and Cytokine Treatment. <i>Blood</i> , 2011, 118, 4402-4402.	1.4	0
179	Kiâ67 expression as a prognostic factor in diffuse large Bâcell lymphoma patients treated with rituximab plus CHOP. <i>European Journal of Haematology</i> , 2010, 85, 149-157.	2.2	34
180	Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 768-773.	1.3	74

#	ARTICLE	IF	CITATIONS
181	S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?. Expert Review of Anticancer Therapy, 2010, 10, 659-662.	2.4	5
182	Comparison of Survival and Clinical Features In Different Age Cohorts of Patients with Multiple Myeloma: A Single Center Experience. Blood, 2010, 116, 4997-4997.	1.4	0
183	PROGNOSTIC SIGNIFICANCE of CD68 EXPRESSION for Korean PATIENTS with HODGKIN'S LYMPHOMA. Blood, 2010, 116, 3888-3888.	1.4	1
184	Percutaneous Management of a Bronchobiliary Fistula after Radiofrequency Ablation in a Patient with Hepatocellular Carcinoma. Korean Journal of Radiology, 2009, 10, 411.	3.4	34
185	Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion, 2009, 49, 1890-1900.	1.6	38
186	Prognostic Impact of Mid-Treatment PET in Patients with Diffuse Large B-Cell Lymphoma Who Achieved Metabolic CR at Post-Treatment PET. Blood, 2009, 114, 3949-3949.	1.4	1
187	SIGNIFICANCE of ABSOLUTE LYMPHOCYTE COUNT at RELAPSE as a PROGNOSTIC FACTOR in PATIENTS with T-CELL NON-HODGKIN'S LYMPHOMA.. Blood, 2009, 114, 2939-2939.	1.4	0
188	VPDL Chemotherapy for T-cell Lymphoblastic Lymphoma (T-LBL) in Adults: Comparison with Upfront Autologous Stem Cell Transplantation in a Single Center. The Korean Journal of Hematology, 2008, 43, 138.	0.7	2
189	Timing of G-CSF Injection for Effective Autologous Stem Cell Collection. Blood, 2008, 112, 4439-4439.	1.4	0
190	Clinical outcomes of early-progressed follicular lymphoma in Korea: a multicenter, retrospective analysis. Archives of Medical Science, 0, , .	0.9	0